Conference Coverage
Conference Coverage
Largest meeting on cancer research canceled: AACR
Conference Coverage
HIV free 30 months after stem cell transplant, is the London patient cured?
Conference Coverage
REGN1979 shows good activity in pretreated aggressive B-NHL
...
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
Zanubrutinib achieved high response rate in del(17p) CLL cohort
ORLANDO – The study looked at responses in a cohort of patients with historically poor prognosis and response to chemotherapy.
Conference Coverage
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
Conference Coverage
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...
Conference Coverage
An off-the-shelf drug to rival CAR T cells: ‘very exciting’
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/...